Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2024 | Overcoming resistance to HER2-directed ADCs in HER2+ breast cancer

Jangsoon Lee • 12 Dec 2024
SABCS 2024
Breast Cancer Antibodies Elimusertib Trastuzumab deruxtecan Trastuzumab emtansine

Jangsoon Lee, PhD, University of Hawai’i Cancer Center, Honolulu, HI, explores mechanisms of resistance to HER2-antibody-drug conjugate (ADC) therapies, such as trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd), and potential strategies to overcome them. Synthetic lethal screening can identify DNA damage repair pathways as key therapeutic targets and combining T-DXd with elimusertib, ATR inhibitor, has demonstrated significant synergy in preclinical models. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jangsoon Lee

Recommendations for physicians on personalized HER2+ breast cancer treatment
1:07
Recommendations for physicians on personalized HER2+ breast cancer treatment
Jangsoon Lee • 12 Dec 2024
Targeting DNA repair pathways for ADC-resistant HER2+ breast cancer
1:07
Targeting DNA repair pathways for ADC-resistant HER2+ breast cancer
Jangsoon Lee • 12 Dec 2024
Emerging strategies to overcome resistance to HER2 ADCs in breast cancer
1:02
Emerging strategies to overcome resistance to HER2 ADCs in breast cancer
Jangsoon Lee • 12 Dec 2024

Related Videos

HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
QoL following hypofractionated adjuvant breast RNRT: insights from the HYPORT study
1:15
QoL following hypofractionated adjuvant breast RNRT: insights from the HYPORT study
Sanjoy Chatterjee • 17 May 2026
Adherence to weight loss intervention in breast cancer patients
1:09
Adherence to weight loss intervention in breast cancer patients
Jennifer Ligibel • 31 May 2026
The content of VJOncology is intended for healthcare professionals